GreenLight XPS is intended to treat benign prostatic hyperplasia (BPH) using photoselective vaporisation of prostatic tissue.
 
Status In progress
Decision Selected
Process MT
ID number 564

Provisional Schedule

Draft guidance: 1 15 June 2022 - 13 July 2022
Resolution 05 September 2022
Expected publication 14 October 2022

Project Team

Project lead Samantha Baskerville

Email enquiries

Stakeholders

External assessment group NUTH
Manufacturers Boston Scientific
Others Association of British Healthcare Industries (ABHI)
  Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
  Boston Scientific
  Department of Health and Social Care
  Devices for Dignity
  Greater Manchester Health & Social Care Partnership
  Health Technology Wales
  Healthcare Improvement Scotland
  HealthTech Alliance
  Johnson & Johnson Medical Ltd
  Medical Technology Group
  Medicines and Healthcare Products Regulatory Agency
  University of Manchester Wounds Research Group
  NHS England
  The British In Vitro Diagnostics Association (BIVDA)
  NHS Digital

Timeline

Key events during the development of the guidance:

Date Update
20 May 2022 Committee meeting: 1
22 October 2021 Scope published
04 October 2021 Stakeholder registration opens

For further information on our processes and methods, please see our CHTE processes and methods manual